dabrafenib + trametinib + ipilimumab

This is a **three-drug combination** composed of dabrafenib (a selective BRAF inhibitor), trametinib (a MEK1/2 inhibitor), and ipilimumab (a monoclonal antibody targeting CTLA-4), studied primarily for the treatment of **BRAF V600-mutant metastatic melanoma**. Dabrafenib and trametinib together inhibit key kinases in the MAPK pathway, suppressing abnormal cell proliferation and survival driven by BRAF mutations. Ipilimumab blocks CTLA-4, resulting in enhanced T cell-mediated antitumor immune responses. The rationale for combining these drugs is to achieve synergistic antitumor effects by both targeting oncogenic signaling and releasing immune checkpoints, though overlapping toxicities are a notable risk.